Lower drug prices into the main theme of down-to-earth do medicine do not worry about no market

to solve the problem of people "expensive to see a doctor", has always been one of the main tasks of the new medical reform, and the price of medicine is inflated, it is the common people "expensive to see a doctor" one of the "culprits." In order to solve the problem of inflated drug prices, both the national and local levels have been trying and exploring, and through the implementation of special procurement of anti-cancer drugs, zero-tariff band procurement, price negotiations and other ways to reduce drug prices. In 2019, under the general trend of "reducing drug prices", it seems that the market or price protection has become a dilemma for pharmaceutical companies. Industry experts said that in order to break through, the fundamental way is to do conscience medicine, quality to win, focus on independent research and development and innovation, so that no one I have, people have me excellent.Drug companies and local governments game "drug prices
In December 2018, Liaoning Province' centralized procurement network of pharmaceuticals and medical supplies issued a "notice on the implementation of domestic anti-cancer drug tax reduction results" (hereinafter referred to as the "Notice"), expressed for the The 125 standard drugs that apply for no price reduction, do not provide relevant supporting materials from accounting firms and do not submit any materials will be suspended from purchase on the Liaoning Provincial Register from 0:00 on December 25, 2018.
statistics, the loss of the network procurement qualifications of a total of 60 pharmaceutical companies, many of which have a number of specifications of products were suspended trading. These drugs that are disqualified are roughly divided into the following situations:
two drugs in the name of "not affected by the tax reduction" to apply for no price reduction, but did not provide relevant supporting materials, not recognized by the collection platform;
However, the following December 29, Jiangsu Hengrui Pharmaceutical Co., Ltd. and other 21 pharmaceutical manufacturers of 42 domestic anti-cancer drugs to apply for tax reduction and resume online procurement, 30 to resume online procurement, and the implementation of the new online procurement qualifications.
It is understood that since May 1, 2018, China has begun to implement anti-cancer drugs and other drugs "zero tariffs", many local governments therefore asked pharmaceutical companies to reduce prices, Liaoning Province, the suspension of drug companies' online procurement qualifications, is for pharmaceutical companies not to reduce prices or price reduction is not in place to take one of the measures. Wei Baixing, founder of drug price reduction networks, disagrees with such moves by local governments. "Is there a lot of jokes from local governments in China's health reform?" he said. Some time ago, Liaoning Province also announced that azithromycin 0.25 g x 6 tablets of the price of nearly 50 yuan, is there a lot of high-priced drugs in their back-office database? Throughout the ten-year process of medical reform, local governments have been deceiving, messing around, think of one out is one out, drug prices are getting higher and higher, even including the price of commonly used drugs. In other words, local governments are the culprits in pushing up drug prices, and they are also the biggest beneficiaries and umbrellas of the health-care reform chain. The
local governments to ask pharmaceutical companies to reduce drug prices on the grounds of tax reduction, this reason is not reasonable. So, what kind of drugs can be reduced in price? Wei Baixing analysis, all can reduce the price of drugs are generally inseparable from two characteristics. The first feature is that such pharmaceutical manufacturers are many, the market saturation, competitive, imitation of the top three pharmaceutical companies no longer need to rely on this product to make money. The price reduction of such drugs, not only in response to the country's "drug price reduction" call, in line with the implementation of local policies, to achieve a good reputation, but also to consolidate the past sales channels, for the enterprise's other drug sales to lay a foundation, can be said to be a lot. The second characteristic is that there are fewer competitors for such drugs, but the drugs themselves have various side effects, such as drug resistance, and companies already have similar new drugs on the market, and the market prospects are good, will naturally reduce the price of such drugs. It's not so much cutting prices as being eliminated from within the company.
in Liaoning Province, Jiangsu Hengrui Pharmaceutical Co., Ltd., Beijing Shuangju Pharmaceutical Co., Ltd., Qilu Pharmaceutical Co., Ltd. and other well-known enterprises are included. For these pharmaceutical companies would rather give up the network procurement qualifications, rather than reduce drug prices, Wei Baixing also gave their own views. He said that in the current medical reform to "drug reform" as the core of the general trend, enterprises would rather abandon the hanging network than reduce prices is because once the price is reduced, and then want to raise the price of drugs almost impossible, such as some exclusive Chinese medicine, metoo medicine and so on. Of course, there is also a reason that companies believe that the government's drug price reform is still a gust of wind, will not last.
Compared with these companies that are reluctant to lower drug prices, the information released by drug procurement in the provinces and cities in the second half of 2018 shows that some pharmaceutical companies, mainly foreign pharmaceutical companies and large domestic pharmaceutical companies, have chosen to actively lower their bid prices. For different pharmaceutical companies these two very different choices, Wei Baixing said, do not reduce prices may not be able to enter the health insurance catalog, the base drug catalog, even if entered into the catalog may be eliminated or replaced by other similar products, so pharmaceutical companies choose to take the initiative to reduce prices have been forced to reduce prices. In addition, foreign pharmaceutical companies and large domestic pharmaceutical companies choose to reduce prices also in line with the aforementioned drug price reduction of the two characteristics.drug price reform is also good for pharmaceutical companies
drug prices involve solving the problem of people "expensive to see a doctor", is one of the main tasks of the new medical reform. But all along, the common people "expensive to see a doctor" problem has not been well resolved. From the end of 2018 4 plus 7 city centralized procurement pilot can be seen that China's drug prices do exist abnormally high situation. As for the cause of the abnormally high drug prices, Wei Said that 20% of chinese and foreign large pharmaceutical companies monopolize 80% of the pharmaceutical market sales share, pharmaceutical companies, hospitals, doctors and power rent-seeking government departments, driven by huge interests, they jointly promote China's drug price abnormally high, especially the government's recruitment department is the core of evil.
the morning of December 28, 2018, the seventh session of the Standing Committee of the 13th National People's Congress held a joint meeting to conduct thematic inquiries on the consideration of the State Council's report on the allocation and use of financial and health funds. Vice Premier Sun Chunlan said that China's drug prices are more prominent, many drugs are more expensive than neighboring countries and regions. To solve the problem of expensive medical treatment, we must first bring down the inflated price of medicine. Mr. Wei agrees. "Premier Li Keqiang made it clear at the executive meeting of the State Council on April 6, 2016 that the 'drug price' should be used as a 'breakthrough' to deepen medical reform," he said. Two years later, Vice Premier Sun also proposed to 'reduce drug prices' as a breakthrough, coupled with the current '4 plus 7 band volume procurement', it can be said that the central government to the core of the current stage of medical reform to adjust the drug price decision is very wise, found out the core pain point of China's medical reform over the years, caught the solution to the 'expensive to see a doctor' 'bull nose'. "
have been trying and exploring at the national and local levels to solve the problem of inflated drug prices. In addition to the implementation of special procurement of anti-cancer drugs, zero tariffs and other measures, the state also through volume procurement, price negotiations and other ways to reduce drug prices. "Drug price reduction" has become a major trend. In this trend, some people in the industry have pointed out that it is not enough to simply reduce drug prices. As the saying goes, it's better to ask for people than to ask for yourself. In the targeted drugs, biopharmaceuticals and other basically monopolized by imported drugs at the present time, through tax reduction and negotiation to reduce drug prices, its role is very limited. After all, people who are inferior to skill have no voice. To really solve the problem of "expensive to see a doctor", the fundamental way out lies in independent research and development and innovation, in technology has always been in a leading state, so that no one I have, people have me excellent, is the direction that Chinese pharmaceutical companies should strive for.
WeiBaiXing also said that since the state came forward to carry out volume procurement, for the past regularly at the edge of the squeeze of small and medium-sized pharmaceutical companies is undoubtedly a great boon, enterprises only put good product quality, retain reasonable profits, in order to reduce the price to the end.
on the one hand, the state is trying to reduce drug prices, but on the other hand, the costs of pharmaceutical companies remain high, such as consistent evaluation, raw material prices, standardized operations, environmental protection, labor and so on. Is the price of the drug being pulled down also means that the benefits of pharmaceutical companies are also being lowered? Some people said that, from a different point of view, in fact, drug price reform for pharmaceutical companies are also good. First, to make competition more transparent, powerful pharmaceutical companies can gain a greater market share. Now the health insurance bureau unified procurement of the signal is: hope that pharmaceutical companies do practical medicine, quality, cost control, naturally there is a market, but also money to earn. Second, it can enable pharmaceutical companies to recover their drug payments more quickly, for example, with the purchase of the winning drug companies can receive 50% advance payment in advance, which is conducive to the pharmaceutical companies to live funds. In addition, the market feedback for first-time national volume procurement was also positive: 25 of the 31 generic drugs were to be bid, with an average price reduction of about 52 per cent, with the largest drop of 96 per cent, with very real results.
also gives its own advice on the development of pharmaceutical companies in 2019. He said that pharmaceutical companies to do conscience medicine, earn reasonable money, improve the level of research and development, quality to win, after all, the era of fake negative marketing has become a thing of the past.